Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Pipeline Review, H2 2017’, provides in depth analysis on Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Cardiovascular, Hematological Disorders, Musculoskeletal Disorders and Women's Health under development targeting Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

AstraZeneca Plc

Bristol-Myers Squibb Co

ValiRx Plc

Zen-Bio Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Overview 6

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 13

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Companies Involved in Therapeutics Development 22

AB Science SA 22

AstraZeneca Plc 23

Bristol-Myers Squibb Co 24

ValiRx Plc 25

Zen-Bio Inc 25

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Drug Profiles 27

dasatinib - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

dasatinib - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

masitinib - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

saracatinib difumarate - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Inhibit FYN Kinase for Obesity and Type 2 Diabetes - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VAL-201 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

VAL-301 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Dormant Products 61

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Discontinued Products 63

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC

2.7.10.2) - Product Development Milestones 64

Featured News & Press Releases 64

Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight 64

Sep 28, 2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017 65

Sep 20, 2017: ValiRx Provides Update on VAL201 68

Sep 14, 2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment 68

Jul 12, 2017: AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients 69

Jul 10, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Sprycel (dasatinib) in Children with Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia 70

Jun 22, 2017: AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association 70

Jun 05, 2017: Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) 72

May 19, 2017: European Medicines Agency Validates Application for Bristol-Myers Squibb's Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia 74

May 18, 2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib) 74

May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting 75

May 17, 2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 76

May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards 78

Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years 80

Mar 20, 2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis 81

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by AB Science SA, H2 2017 23

Pipeline by AstraZeneca Plc, H2 2017 24

Pipeline by Bristol-Myers Squibb Co, H2 2017 25

Pipeline by ValiRx Plc, H2 2017 25

Pipeline by Zen-Bio Inc, H2 2017 26

Dormant Products, H2 2017 61

Dormant Products, H2 2017 (Contd..1), H2 2017 62

Discontinued Products, H2 2017 63

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports